Experimental drug may offer more protection from RSV

12/16/2009 | Medscape (free registration)

Researchers reported in Pediatrics that the investigational drug motavizumab may protect children at high risk for respiratory syncytial virus better than palivizumab. Study data showed motavizumab reduced the risk of RSV hospitalization by 26% and the risk of outpatient RSV-related lower respiratory tract infection by 50%.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA